On October 26, 2021 Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, reported that the Company intends to release its operational highlights and financial results for the quarter ended September 30, 2021 on Wednesday, November 3, 2021, and to host a conference call the same day at 4:30 p.m. ET (Press release, Synthetic Biologics, OCT 26, 2021, View Source [SID1234591966]). The dial-in information for the call is as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at View Source." target="_blank" title="View Source." rel="nofollow">View Source An archived replay of the call will be available for approximately ninety (90) days at the same URL, View Source beginning approximately one hour after the call’s conclusion.

On October 26, 2021 Nektar Therapeutics (Nasdaq: NKTR) reported that it will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of U.S.-based financial markets (Press release, Nektar Therapeutics, OCT 26, 2021, View Source [SID1234591984]). Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: View Source The web broadcast of the conference call will be available for replay through December 6, 2021.

To access the conference call, follow these instructions:

Dial: (877) 881-2183 (U.S); (970) 315-0453 (international)
Conference ID: 8264398 (Nektar Therapeutics is the host)

On October 26, 2021 Celon Pharma SA reported that it will take part in the 12th edition of the largest European conference on life science (Press release, Celon Pharma, OCT 26, 2021, View Source [SID1234591951]). The conference will be attended by leading companies from the pharmaceutical, biotechnology, medical technology and healthcare services sectors from the Americas, Europe, the Middle East, Africa, Asia and Australia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This conference is a must on the map of our investor relations activities, as well as the development of our business. In this edition, we will focus on maintaining relations with our foreign investors who took part in the last issue, as well as hold a series of business meetings concerning both the area of ​​generic and innovative business development – Dr. Maciej Wieczorek, President of the Management Board of Celon Pharma SA The representatives of the Company will be available in virtual one-to-one sessions, for interested parties on November 18 and 19, 2021. To register, please contact a Jefferies representative: [email protected]

On October 26, 2021 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported plans to release its financial results for the third quarter ended September 30, 2021, on Thursday, November 4, 2021 before the opening of the financial markets (Press release, Akebia, OCT 26, 2021, View Source [SID1234591967]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Akebia will host a conference call Tuesday, November 9 at 9:00 a.m. ET to discuss its third quarter financial results and recent business highlights. Executives will highlight publications and scientific presentations of vadadustat global Phase 3 clinical data, which will be presented at the American Society of Nephrology Kidney Week 2021 beginning November 4, 2021. The Company will also discuss pre-commercialization readiness activities that are underway in anticipation of its March 29, 2022 Prescription Drug User Fee Act (PDUFA) target action date for vadadustat, which is under review by the U.S. Food and Drug Administration as a treatment for anemia due to chronic kidney disease.

To listen to the conference call on November 9th, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 5389484. The call will also be webcast LIVE and can be accessed via the Investors section of the Company’s website at View Source

A replay of the conference call will be available two hours after the completion of the call through November 15, 2021. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number 5389484. An online archive of the conference call can be accessed via the Investors section of the Company’s website at View Source

On October 26, 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that it will report its 2021 third quarter financial results on Tuesday, November 9, 2021 after the close of the U.S. financial markets (Press release, Jazz Pharmaceuticals, OCT 26, 2021, View Source [SID1234591985]). Company management will host a live audio webcast at 4:30 p.m. ET/9:30 p.m. IST to discuss 2021 third quarter financial results and provide a business and financial update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharma.com.